Logo image of SYM

SYMBOTIC INC (SYM) Stock Fundamental Analysis

NASDAQ:SYM - Nasdaq - US87151X1019 - Common Stock - Currency: USD

33.5  +0.21 (+0.63%)

After market: 33.6288 +0.13 (+0.38%)

Fundamental Rating

4

Overall SYM gets a fundamental rating of 4 out of 10. We evaluated SYM against 131 industry peers in the Machinery industry. The financial health of SYM is average, but there are quite some concerns on its profitability. SYM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SYM had negative earnings in the past year.
SYM had a negative operating cash flow in the past year.
In the past 5 years SYM always reported negative net income.
In multiple years SYM reported negative operating cash flow during the last 5 years.
SYM Yearly Net Income VS EBIT VS OCF VS FCFSYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

SYM's Return On Assets of -0.85% is on the low side compared to the rest of the industry. SYM is outperformed by 67.72% of its industry peers.
SYM's Return On Equity of -6.84% is on the low side compared to the rest of the industry. SYM is outperformed by 70.87% of its industry peers.
Industry RankSector Rank
ROA -0.85%
ROE -6.84%
ROIC N/A
ROA(3y)-1.41%
ROA(5y)-24.27%
ROE(3y)-9735.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SYM Yearly ROA, ROE, ROICSYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

1.3 Margins

SYM has a Gross Margin of 13.74%. This is amonst the worse of the industry: SYM underperforms 85.83% of its industry peers.
In the last couple of years the Gross Margin of SYM has grown nicely.
SYM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y49.29%
GM growth 5YN/A
SYM Yearly Profit, Operating, Gross MarginsSYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

SYM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SYM has been increased compared to 1 year ago.
SYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SYM Yearly Shares OutstandingSYM Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
SYM Yearly Total Debt VS Total AssetsSYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

SYM has an Altman-Z score of 8.47. This indicates that SYM is financially healthy and has little risk of bankruptcy at the moment.
SYM has a better Altman-Z score (8.47) than 89.76% of its industry peers.
SYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.47
ROIC/WACCN/A
WACC9.68%
SYM Yearly LT Debt VS Equity VS FCFSYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

SYM has a Current Ratio of 1.33. This is a normal value and indicates that SYM is financially healthy and should not expect problems in meeting its short term obligations.
SYM has a Current ratio of 1.33. This is amonst the worse of the industry: SYM underperforms 82.68% of its industry peers.
SYM has a Quick Ratio of 1.23. This is a normal value and indicates that SYM is financially healthy and should not expect problems in meeting its short term obligations.
SYM's Quick ratio of 1.23 is in line compared to the rest of the industry. SYM outperforms 47.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 1.23
SYM Yearly Current Assets VS Current LiabilitesSYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

SYM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.53%, which is quite impressive.
The Revenue has grown by 51.94% in the past year. This is a very strong growth!
Measured over the past years, SYM shows a very strong growth in Revenue. The Revenue has been growing by 77.99% on average per year.
EPS 1Y (TTM)88.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.5%
Revenue 1Y (TTM)51.94%
Revenue growth 3Y92.19%
Revenue growth 5Y77.99%
Sales Q2Q%47.18%

3.2 Future

Based on estimates for the next years, SYM will show a very strong growth in Earnings Per Share. The EPS will grow by 147.85% on average per year.
Based on estimates for the next years, SYM will show a very strong growth in Revenue. The Revenue will grow by 26.47% on average per year.
EPS Next Y838.08%
EPS Next 2Y314.13%
EPS Next 3Y188.5%
EPS Next 5Y147.85%
Revenue Next Year31.92%
Revenue Next 2Y30.62%
Revenue Next 3Y27.43%
Revenue Next 5Y26.47%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SYM Yearly Revenue VS EstimatesSYM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B
SYM Yearly EPS VS EstimatesSYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SYM. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 116.38, the valuation of SYM can be described as expensive.
Based on the Price/Forward Earnings ratio, SYM is valued a bit more expensive than the industry average as 69.29% of the companies are valued more cheaply.
SYM is valuated expensively when we compare the Price/Forward Earnings ratio to 24.51, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 116.38
SYM Price Earnings VS Forward Price EarningsSYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYM Per share dataSYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SYM's earnings are expected to grow with 188.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y314.13%
EPS Next 3Y188.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SYM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYMBOTIC INC

NASDAQ:SYM (1/23/2025, 9:33:03 PM)

After market: 33.6288 +0.13 (+0.38%)

33.5

+0.21 (+0.63%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)11-18 2024-11-18/amc
Earnings (Next)02-03 2025-02-03/bmo
Inst Owners81.12%
Inst Owner Change0.08%
Ins Owners0.34%
Ins Owner Change0.07%
Market Cap19.68B
Analysts72
Price Target34.9 (4.18%)
Short Float %18.06%
Short Ratio6.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-77.99%
Min EPS beat(2)-157.01%
Max EPS beat(2)1.03%
EPS beat(4)2
Avg EPS beat(4)-30.02%
Min EPS beat(4)-157.01%
Max EPS beat(4)69.2%
EPS beat(8)3
Avg EPS beat(8)-51.36%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)13.13%
Min Revenue beat(2)4.83%
Max Revenue beat(2)21.43%
Revenue beat(4)3
Avg Revenue beat(4)6.73%
Min Revenue beat(4)-1.1%
Max Revenue beat(4)21.43%
Revenue beat(8)7
Avg Revenue beat(8)11.79%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.2%
PT rev (3m)-15.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5%
Revenue NY rev (1m)-0.68%
Revenue NY rev (3m)-2.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 116.38
P/S 11
P/FCF N/A
P/OCF N/A
P/B 99.77
P/tB 101.66
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)0.29
Fwd EY0.86%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS3.04
BVpS0.34
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.85%
ROE -6.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.74%
FCFM N/A
ROA(3y)-1.41%
ROA(5y)-24.27%
ROE(3y)-9735.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y49.29%
GM growth 5YN/A
F-Score4
Asset Turnover1.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 179.89%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 1.23
Altman-Z 8.47
F-Score4
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)206.19%
Cap/Depr(5y)195.83%
Cap/Sales(3y)2.24%
Cap/Sales(5y)3.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.5%
EPS Next Y838.08%
EPS Next 2Y314.13%
EPS Next 3Y188.5%
EPS Next 5Y147.85%
Revenue 1Y (TTM)51.94%
Revenue growth 3Y92.19%
Revenue growth 5Y77.99%
Sales Q2Q%47.18%
Revenue Next Year31.92%
Revenue Next 2Y30.62%
Revenue Next 3Y27.43%
Revenue Next 5Y26.47%
EBIT growth 1Y47.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year289.33%
EBIT Next 3Y108.6%
EBIT Next 5Y83.91%
FCF growth 1Y-146.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-125.16%
OCF growth 3YN/A
OCF growth 5YN/A